RAYMOND E , FAIVRE S , WOYNAROWSKI J M , et al . Oxaliplatin: mechanism of action and antineoplastic activity [J ] . Semin Oncol , 1998 , 25 (2 Suppl 5): 4 - 12 .

DEVANABANDA B , KASI A . Oxaliplatin [J ] . Stat Pearls , 2023 .

RASSY E , LE ROY F , SMOLENSCHI C , et al . Rechallenge after oxaliplatin-induced hypersensitivity reactions [J ] . JAMA Oncol , 2023 , 9 ( 3 ): 434 - 435 . DOI: 10.1001/jamaoncol.2022.7136 http://doi.org/10.1001/jamaoncol.2022.7136

GAO T Y , TAO Y T , LI H Y , et al . Cancer burden and risk in the Chinese population aged 55 years and above: a systematic analysis and comparison with the USA and Western Europe [J ] . J Glob Health , 2024 , 14 : 04014 .

郭兰伟 , 张兴龙 , 蔡林 , 等 . 全球结直肠癌流行和防控现状 [J ] . 中华肿瘤杂志 , 2024 , 46 ( 1 ): 57 - 65 .

GUO L W , ZHANG X L , CAI L , et al . Current status of global colorectal cancer prevalence, prevention and control [J ] . Chin J Oncol , 2024 , 46 ( 1 ): 57 - 65 .

EDWARDS I R , ARONSON J K . Adverse drug reactions: definitions, diagnosis, and management [J ] . Lancet , 2000 , 356 ( 9237 ): 1255 - 1259 . DOI: 10.1016/S0140-6736(00)02799-9 http://doi.org/10.1016/S0140-6736(00)02799-9

SCHNYDER B , PICHLER W J . Mechanisms of drug-induced allergy [J ] . Mayo Clin Proc , 2009 , 84 ( 3 ): 268 - 272 . DOI: 10.1016/S0025-6196(11)61145-2 http://doi.org/10.1016/S0025-6196(11)61145-2

PICHLER W J . Immune pathomechanism and classification of drug hypersensitivity [J ] . Allergy , 2019 , 74 ( 8 ): 1457 - 1471 . DOI: 10.1111/all.13765 http://doi.org/10.1111/all.13765

DOÑA I , CAUBET J C , BROCKOW K , et al . An EAACI task force report: recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity [J ] . Clin Transl Allergy , 2018 , 8 : 16 . DOI: 10.1186/s13601-018-0202-2 http://doi.org/10.1186/s13601-018-0202-2

BROCKOW K , WURPTS G , TRAUTMANN A , et al . Guideline for allergological diagnosis of drug hypersensitivity reactions: S2k guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in cooperation with the German Dermatological Society (DDG), the Association of German Allergologists (ÄDA), the German Society for Pediatric Allergology (GPA), the German Contact Dermatitis Research Group (DKG), the German Society for Pneumology (DGP), the German Society of Otorhinolaryngology, Head and Neck Surgery, the Austrian Society of Allergology and Immunology (ÖGAI), the Austrian Society of Dermatology and Venereology (ÖGDV), the German Academy of Allergology and Environmental Medicine (DAAU), and the German Documentation Center for Severe Skin Reactions (dZh) [J ] . Allergol Select , 2023 , 7 : 122 - 139 .

COOMBS P R , GELL P G . Classification of allergic reactions responsible for clinical hypersensitivity and disease . In: Gell RR , ed. Clinical aspects of immunology [M ] . Oxford University Press, 1968 : 575 - 590 .

CARDONA V , ANSOTEGUI I J , EBISAWA M , et al . World allergy organization anaphylaxis guidance 2020 [J ] . World Allergy Organ J , 2020 , 13 ( 10 ): 100472.

TURNER P J , WORM M , ANSOTEGUI I J , et al . Time to revisit the definition and clinical criteria for anaphylaxis? [J ] . World Allergy Organ J , 2019 , 12 ( 10 ): 100066.

PALAPINYO S , KLAEWSONGKRAM J , SRIURANPONG V , et al . Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: a 5-year retrospective study [J ] . Pharm Pract , 2022 , 20 ( 2 ): 2635.

BARBIN F , GHIDINI M , PANICHI A , et al . Oxaliplatin-related hypersensitivity reactions: a single institution series and literature review [J ] . Biomedicines , 2022 , 10 ( 12 ): 3275.

PAGANI M , BAVBEK S , ALVAREZ-CUESTA E , et al . Hypersensitivity reactions to chemotherapy: an EAACI position paper [J ] . Allergy , 2022 , 77 ( 2 ): 388 - 403 .

SEKI K , SENZAKI K , TSUDUKI Y , et al . Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer [J ] . Int J Med Sci , 2011 , 8 ( 3 ): 210 - 215 . DOI: 10.7150/ijms.8.210 http://doi.org/10.7150/ijms.8.210

ANDRÉ T , BONI C , MOUNEDJI-BOUDIAF L , et al . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J ] . N Engl J Med , 2004 , 350 ( 23 ): 2343 - 2351 .

DE GRAMONT A , FIGER A , SEYMOUR M , et al . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J ] . J Clin Oncol , 2000 , 18 ( 16 ): 2938 - 2947 . DOI: 10.1200/JCO.2000.18.16.2938 http://doi.org/10.1200/JCO.2000.18.16.2938

GIACCHETTI S , PERPOINT B , ZIDANI R , et al . Phase Ⅲ multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [J ] . J Clin Oncol , 2000 , 18 ( 1 ): 136 - 147 .

李惠 , 林榕波 , 林娇 , 等 . 奥沙利铂脱敏治疗及皮试的探索性研究 [J ] . 现代肿瘤医学 , 2018 , 26 ( 18 ): 2948 - 2952 .

LI H , LIN R B , LIN J , et al . Exploratory study of oxaliplatin desensitization and skin test [J ] . J Mod Oncol , 2018 , 26 ( 18 ): 2948 - 2952 .

MORI Y , NISHIMURA T , KITANO T , et al . Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX [J ] . Oncology , 2010 , 79 ( 1/2 ): 136 - 143 .

SILVER J , GARCIA-NEUER M , LYNCH D M , et al . Endophenotyping oxaliplatin hypersensitivity: personalizing desensitization to the atypical platin [J ] . J Allergy Clin Immunol Pract , 2020 , 8 ( 5 ): 1668 - 1680 .e2. DOI: S2213-2198(20)30172-0 http://doi.org/S2213-2198(20)30172-0

LEONARD G D , WRIGHT M A , QUINN M G , et al . Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer [J ] . BMC Cancer , 2005 , 5 : 116 .

DEMOLY P , PICHLER W , PIRMOHAMED M , et al . Important questions in allergy: 1: drug allergy/hypersensitivity [J ] . Allergy , 2008 , 63 ( 5 ): 616 - 619 .

BAVBEK S , PAGANI M , ALVAREZ-CUESTA E , et al . Hypersensitivity reactions to biologicals: an EAACI position paper [J ] . Allergy , 2022 , 77 ( 1 ): 39 - 54 .

TONINI G , SANTINI D , VINCENZI B , et al . Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients [J ] . J Biol Regul Homeost Agents , 2002 , 16 ( 2 ): 105 - 109 .

SHAKER M S , WALLACE D V , GOLDEN D B K , et al . Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis [J ] . J Allergy Clin Immunol , 2020, 145 ( 4 ): 1082 - 1123 .

GOLDEN D B K , WANG J L , WASERMAN S , et al . Anaphylaxis: a 2023 practice parameter update [J ] . Ann Allergy Asthma Immunol , 2024 , 132 ( 2 ): 124 - 176 .

National Cancer Institute . Common terminology criteria for adverse events (CTCAE) version 5.0. 2017 [EB/OL ] . https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf

BROWN S G A . Clinical features and severity grading of anaphylaxis [J ] . J Allergy Clin Immunol , 2004 , 114 ( 2 ): 371 - 376 .

PAREL M , RANCHON F , NOSBAUM A , et al . Hypersensitivity to oxaliplatin: clinical features and risk factors [J ] . BMC Pharmacol Toxicol , 2014 , 15 : 1 .

SELCUK A , YILDIZ B . Oxaliplatin-induced hypersensitivity reactions: risk factors and management [J ] . Eur Rev Med Pharmacol Sci , 2023 , 27 ( 6 ): 2640 - 2645 .

SUGIHARA K , OHTSU A , SHIMADA Y , et al . Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies [J ] . Clin Colorectal Cancer , 2012 , 11 ( 2 ): 127 - 137 .

HAN J Y , PAN C , TANG X , et al . Hypersensitivity reactions to small molecule drugs [J ] . Front Immunol , 2022 , 13 : 1016730 .

SAKAMOTO E , KATAHIRA Y , MIZOGUCHI I , et al . Chemical- and drug-induced allergic, inflammatory, and autoimmune diseases via haptenation [J ] . Biology , 2023 , 12 ( 1 ): 123.

ZHU L H , LI H , DU Q , et al . Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients [J ] . Int J Clin Oncol , 2021 , 26 ( 12 ): 2194 - 2204 . DOI: 10.1007/s10147-021-02034-3 http://doi.org/10.1007/s10147-021-02034-3

Medicinal products containing lactose of bovine origin for IV/IM use in acute allergic reactions-referral [EB/OL ] . https://www.ema.europa.eu/en/medicines/human/referrals/medicinal-products-containing-lactose-bovine-origin-iv-im-use-acute-allergic-reactions. https://www.ema.europa.eu/en/medicines/human/referrals/medicinal-products-containing-lactose-bovine-origin-iv-im-use-acute-allergic-reactions https://www.ema.europa.eu/en/medicines/human/referrals/medicinal-products-containing-lactose-bovine-origin-iv-im-use-acute-allergic-reactions

OKAYAMA T , ISHIKAWA T , SUGATANI K , et al . Hypersensitivity reactions to oxaliplatin: identifying the risk factors and judging the efficacy of a desensitization protocol [J ] . Clin Ther , 2015 , 37 ( 6 ): 1259 - 1269 . DOI: 10.1016/j.clinthera.2015.03.012 http://doi.org/10.1016/j.clinthera.2015.03.012

SOHN K H , KANG D Y , KIM J Y , et al . Incidence and risk of oxaliplatin-induced hypersensitivity in patients with asymptomatic prior exposure: a prospective observational study [J ] . J Allergy Clin Immunol Pract , 2018 , 6 ( 5 ): 1642 - 1648 .e2.

SONG Q Y , CAI Y X , GUO K Y , et al . Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer [J ] . Am J Transl Res , 2022 , 14 ( 4 ): 2461 - 2468 .

PAGANI M , BONADONNA P . Skin test protocol for the prevention of hypersensitivity reactions to oxaliplatin [J ] . Anticancer Res , 2014 , 34 ( 1 ): 537 - 540 .

ANSOTEGUI I J , MELIOLI G , CANONICA G W , et al . IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper [J ] . World Allergy Organ J , 2020 , 13 ( 2 ): 100080.

BROCKOW K , GARVEY L H , ABERER W , et al . Skin test concentrations for systemically administered drugs-anENDA/EAACIDrug Allergy Interest Group position paper [J ] . Allergy , 2013 , 68 ( 6 ): 702 - 712 .

PAGANI M , BONADONNA P , SENNA G E , et al . Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin [J ] . Int Arch Allergy Immunol , 2008 , 145 ( 1 ): 54 - 57 .

ROGERS B B , CUDDAHY T , BRISCELLA C , et al . Oxaliplatin: detection and management of hypersensitivity reactions [J ] . Clin J Oncol Nurs , 2019 , 23 ( 1 ): 68 - 75 . DOI: 10.1188/19.CJON.68-75 http://doi.org/10.1188/19.CJON.68-75

ALVAREZ-CUESTA E , MADRIGAL-BURGALETA R , ANGEL-PEREIRA D , et al . Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization [J ] . Allergy , 2015 , 70 ( 7 ): 784 - 794 .

GORGULU AKIN B , ERKOC M , KORKMAZ E T , et al . Rapid drug desensitization with platin-based chemotherapy: analysis of risk factors for breakthrough reactions [J ] . World Allergy Organ J , 2022 , 15 ( 1 ): 100619.

JIMENEZ-RODRIGUEZ T W , DE LAS VECILLAS L , LABELLA M , et al . differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: phenotypes, endotypes, and management with desensitization [J ] . Allergy , 2024 , 79 ( 3 ): 679 - 689 .

CAIADO J , VENEMALM L , PEREIRA-SANTOS M C , et al . Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy [J ] . J Allergy Clin Immunol Pract , 2013 , 1 ( 5 ): 494 - 500 . DOI: 10.1016/j.jaip.2013.06.002 http://doi.org/10.1016/j.jaip.2013.06.002

MADRIGAL-BURGALETA R , BERNAL-RUBIO L , BERGES-GIMENO M P , et al . A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents [J ] . J Allergy Clin Immunol Pract , 2019 , 7 ( 2 ): 618 - 632 .

CAIADO J , BRÁS R , PAULINO M , et al . Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic: outcomes and risk factors [J ] . Ann Allergy Asthma Immunol , 2020 , 125 ( 3 ): 325 - 333 .e1.

SANTOS A F , ALPAN O , HOFFMANN H J . Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice [J ] . Allergy , 2021 , 76 ( 8 ): 2420 - 2432 .

ORNELAS C , CAIADO J , CAMPOS MELO A , et al . The contribution of the basophil activation test to the diagnosis of hypersensitivity reactions to oxaliplatin [J ] . Int Arch Allergy Immunol , 2018 , 177 ( 3 ): 274 - 280 .

GIAVINA-BIANCHI P , GALVÃO V R , PICARD M , et al . Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy [J ] . J Allergy Clin Immunol Pract , 2017 , 5 ( 3 ): 728 - 736 .

MURARO A , WORM M , ALVIANI C , et al . EAACI guidelines: anaphylaxis (2021 update) [J ] . Allergy , 2022 , 77 ( 2 ): 357 - 377 .

ALQURASHI W , ELLIS A K . Do corticosteroids prevent biphasic anaphylaxis? [J ] . J Allergy Clin Immunol Pract , 2017 , 5 ( 5 ): 1194 - 1205 . DOI: S2213-2198(17)30385-9 http://doi.org/S2213-2198(17)30385-9

LIU X W , LEE S , LOHSE C M , et al . Biphasic reactions in emergency department anaphylaxis patients: a prospective cohort study [J ] . J Allergy Clin Immunol Pract , 2020 , 8 ( 4 ): 1230 - 1238 . DOI: S2213-2198(19)30918-3 http://doi.org/S2213-2198(19)30918-3

李晓桐 , 郑航慈 , 门鹏 , 等 . 《严重过敏反应急救指南》计划书 [J ] . 药物流行病学杂志 , 2020 , 29 ( 3 ): 193 - 197 .

LI X T , ZHENG H C , MEN P , et al . Protocol of the guideline for emergency management of anaphylaxis [J ] . Chin J Pharmacoepidemiol , 2020 , 29 ( 3 ): 193 - 197 .

CAMPBELL R L , BELLOLIO M F , KNUTSON B D , et al . Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine [J ] . J Allergy Clin Immunol Pract , 2015 , 3 ( 1 ): 76 - 80 . DOI: 10.1016/j.jaip.2014.06.007 http://doi.org/10.1016/j.jaip.2014.06.007

SIEMIENIUK R A C , CHU D K , KIM L H , et al . Oxygen therapy for acutely ill medical patients: a clinical practice guideline [J ] . BMJ , 2018 , 363 : k4169 .

NURMATOV U B , RHATIGAN E , ESTELLE R SIMONS F , et al . H2-antihistamines for the treatment of anaphylaxis with and without shock: a systematic review [J ] . Ann Allergy Asthma Immunol , 2014 , 112 ( 2 ): 126 - 131 .

CAMPBELL D E . Anaphylaxis management: time to re-evaluate the role of corticosteroids [J ] . J Allergy Clin Immunol Pract , 2019 , 7 ( 7 ): 2239 - 2240 . DOI: S2213-2198(19)30621-X http://doi.org/S2213-2198(19)30621-X

MCHUGH K , REPANSHEK Z . Anaphylaxis: emergency department treatment [J ] . Emerg Med Clin North Am , 2022 , 40 ( 1 ): 19 - 32 .

TUPPER J , VISSER S . Anaphylaxis: a review and update [J ] . Can Fam Physician , 2010 , 56 ( 10 ): 1009 - 1011 .

HONORE P M , REDANT S , PRESEAU T , et al . Refractory anaphylaxis needing emergency intubation supported by expert opinion and published guidelines: could we use off-label drugs to avoid it? [J ] . Crit Care Med , 2022 , 50 ( 5 ): e498-e499.

SOAR J , BECKER L B , BERG K M , et al . Cardiopulmonary resuscitation in special circumstances [J ] . Lancet , 2021 , 398 ( 10307 ): 1257 - 1268 .

THOMAS M , CRAWFORD I . Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers [J ] . Emerg Med J , 2005 , 22 ( 4 ): 272 - 273 .

SIMONS F E , GU X , JOHNSTON L M , et al . Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis? [J ] . Pediatrics , 2000 , 106 ( 5 ): 1040 - 1044 .

THOMAS R R , QUINN M G , SCHULER B , et al . Hypersensitivity and idiosyncratic reactions to oxaliplatin [J ] . Cancer , 2003 , 97 ( 9 ): 2301 - 2307 .

BANO N , NAJAM R , QAZI F , et al . Clinical features of oxaliplatin induced hypersensitivity reactions and therapeutic approaches [J ] . Asian Pac J Cancer Prev , 2016 , 17 ( 4 ): 1637 - 1641 .

KENDIRLINAN R , GÜMÜŞBURUN R , ÇERÇI P , et al . Rapid drug desensitization with chemotherapeutics (platins, taxanes, and others): a single-center retrospective study [J ] . Int Arch Allergy Immunol , 2019 , 179 ( 2 ): 114 - 122 .

KANG Y , KWON O Y , JUNG H , et al . Breakthrough reactions during rapid drug desensitization: clinical outcome and risk factors [J ] . Ann Allergy Asthma Immunol , 2019 , 123 ( 1 ): 48 - 56 .e1.

上海市抗癌协会癌症康复与姑息治疗专业委员会 , 上海市抗癌协会肿瘤药物临床研究专业委员会 , 中国老年保健协会肿瘤防治与临床研究管理专业委员会 , 等 . 抗肿瘤治疗所致恶心呕吐全程管理上海专家共识(2024年版) [J ] . 中国癌症杂志 , 2024 , 34 ( 1 ): 104 - 133 . DOI: 10.19401/j.cnki.1007-3639.2024.01.008 http://doi.org/10.19401/j.cnki.1007-3639.2024.01.008

Shanghai Anti Cancer Association Cancer Rehabilitation and Palliative Treatment Professional Committee , Shanghai Anti Cancer Association Tumor Drug Clinical Research Professional Committee , China Elderly Health Care Association Tumor Prevention and Clinical Research Management Professional Committee , et al . Shanghai expert consensus on whole-process management of antineoplastic-induced nausea and vomiting (2024 edition) [J ] . China Oncol , 2024 , 34 ( 1 ): 104 - 133 .

KIDERA Y , SATOH T , UEDA S , et al . High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin [J ] . Int J Clin Oncol , 2011 , 16 ( 3 ): 244 - 249 . DOI: 10.1007/s10147-010-0170-6 http://doi.org/10.1007/s10147-010-0170-6

ZHAO S , SU L Y , HUANG F , et al . Phase Ⅰ trial of apatinib and paclitaxel+oxaliplatin+5-FU/levoleucovorin for treatment-naïve advanced gastric cancer [J ] . Cancer Sci , 2024 , 115 ( 5 ): 1611 - 1621 .

SHIBATA Y , ARIYAMA H , BABA E S , et al . Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan [J ] . Int J Clin Oncol , 2009 , 14 ( 5 ): 397 - 401 . DOI: 10.1007/s10147-009-0883-6 http://doi.org/10.1007/s10147-009-0883-6

BRANDI G , PANTALEO M A , GALLI C , et al . Hypersensitivity reactions related to oxaliplatin (OHP) [J ] . Br J Cancer , 2003 , 89 ( 3 ): 477 - 481 .

YOSHIDA Y , HIRATA K , MATSUOKA H , et al . A single-arm phase Ⅱ validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial [J ] . Drug Des Devel Ther , 2015 , 9 : 6067 - 6073 .

OHTA H , HAYASHI T , MURAI S , et al . Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer [J ] . Cancer Chemother Pharmacol , 2017 , 79 ( 5 ): 1021 - 1029 .

YANAI T , IWASA S , HASHIMOTO H , et al . Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer [J ] . Anticancer Res , 2012 , 32 ( 12 ): 5521 - 5526 .

CASTELLS M . Rapid desensitization for hypersensitivity reactions to medications [J ] . Immunol Allergy Clin North Am , 2009 , 29 ( 3 ): 585 - 606 .

TUNAKAN DALGIC C , CAMYAR A , METE GOKMEN N , et al . Interdisciplinary healthcare team experience of carboplatin and oxaliplatin desensitizations in a tertiary referral university hospital [J ] . J Asthma Allergy , 2023 , 16 : 743 - 753 . DOI: 10.2147/JAA.S419722 http://doi.org/10.2147/JAA.S419722

CERNADAS J R , BROCKOW K , ROMANO A , et al . General considerations on rapid desensitization for drug hypersensitivity-a consensus statement [J ] . Allergy , 2010 , 65 ( 11 ): 1357 - 1366 .

BERGES-GIMENO M P , CARPIO-ESCALONA L V , LONGO-MUÑOZ F , et al . Does rapid drug desensitization to chemotherapy affect survival outcomes? [J ] . J Investig Allergol Clin Immunol , 2020 , 30 ( 4 ): 254 - 263 .

STEIN S , DOOLEY K , UBOHLA N V , et al . A pilot study of omalizumab to treat oxaliplatin-induced hypersensitivity reaction [J ] . Oncology , 2022 , 36 ( 7 ): 414 - 419 .